FY2025 EPS Estimates for Hims & Hers Health, Inc. Analyst Improved (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) – Equities research analysts at Seaport Res Ptn boosted their FY2025 earnings per share (EPS) estimates for Hims & Hers Health in a research note issued on Monday, August 5th. Seaport Res Ptn analyst A. Kessler now anticipates that the company will post earnings of $0.54 per share for the year, up from their prior estimate of $0.37. Seaport Res Ptn has a “Buy” rating on the stock. The consensus estimate for Hims & Hers Health’s current year earnings is $0.20 per share.

Several other research analysts have also recently commented on HIMS. Canaccord Genuity Group initiated coverage on His & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target for the company. Piper Sandler restated a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research note on Tuesday. Truist Financial boosted their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. TD Cowen boosted their price target on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.57, according to MarketBeat.

View the latest inventory report on HIMS

Price performance for his and her health

Shares of Hims & Hers Health stock opened at $15.91 on Thursday. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of -1,604.00 and a beta of 1.08. The stock’s 50-day moving average is $21.28 and its 200-day moving average is $15.86. Hims & Hers Health has a one year low of $5.65 and a one year high of $25.74.

Hims & Hers Health (NYSE:HIMS – Get Free Report ) last issued its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. The firm had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company’s revenue for the quarter was up 51.8% year over year. During the same period last year, the company posted ($0.03) earnings per share.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,503 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $12.33, for a total value of $30,861.99. Following the sale, the insider now owns 159,357 shares in the company, valued at approximately $1,964,871.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Soleil Boughton sold 2,503 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $12.33, for a total transaction of $30,861.99. Following the transaction, the insider now directly owns 159,357 shares of the company’s stock, valued at approximately $1,964,871.81. The transaction was disclosed in a filing with the SEC, which can be accessed via this link. Also, COO Melissa Baird sold 16,784 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $17.00, for a total value of $285,328.00. Following the transaction, the chief operating officer now directly owns 585,800 shares in the company, valued at $9,958,600. The disclosure for this sale can be found here. In the last quarter, insiders sold 980,907 shares of company stock worth $19,445,689. Insiders own 17.71% of the company’s shares.

Institutional trade of his and her Health

Several institutional investors and hedge funds have recently modified their holdings of HIMS. Allspring Global Investments Holdings LLC boosted its stake in Hims & Hers Health by 103.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 43,662 shares of the company’s stock worth $389,000 after purchasing an additional 22,170 shares in the last quarter. Custom Index Systems LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter valued at about $132,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Hims & Hers Health by 5.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock valued at $261,000 after buying an additional 1,561 shares during the period. Russell Investments Group Ltd. grew its holdings in Hims & Hers Health by 30.7% during the fourth quarter. Russell Investments Group Ltd. now owns 167,328 shares of the company’s stock valued at $1,489,000 after buying an additional 39,337 shares during the period. Finally, Certuity LLC bought a new position in Hims & Hers Health in the fourth quarter valued at $109,000. 63.52% of the shares are held by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

(Get a free report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers with licensed healthcare professionals in the United States, United Kingdom and internationally. The Company offers a range of prescription and over-the-counter health and wellness products and services available for purchase on its websites and mobile application directly by customers.

Featured stories

Get daily Hims & Hers Health news and reviews – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hims & Hers Health and related companies with MarketBeat.com ‘s FREE daily email newsletter.